Literature DB >> 21923615

Pemphigoid diseases: pathogenesis, diagnosis, and treatment.

Michael Kasperkiewicz1, Detlef Zillikens, Enno Schmidt.   

Abstract

Pemphigoid diseases (including bullous pemphigoid, mucous membrane pemphigoid, pemphigoid gestationis, linear IgA dermatosis, lichen planus pemphigoides, and anti-p200 pemphigoid) are a subgroup of autoimmune bullous skin diseases characterized by an autoantibody response toward structural components of the hemidesmosome resulting in subepidermal blistering. By the use of different in vitro systems and experimental animal models, the pathogenic relevance of these autoantibodies has been demonstrated. Recent advances in the understanding of autoantibody responses have led to novel diagnostic tools and a more differentiated therapeutic approach for these disorders. This review covers the most recent understanding of the pathophysiology, diagnosis, and treatment of this group of autoimmune diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21923615     DOI: 10.3109/08916934.2011.606447

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  27 in total

Review 1.  [Involvement of mucous membranes in autoimmune bullous diseases].

Authors:  C Günther
Journal:  Hautarzt       Date:  2016-10       Impact factor: 0.751

2.  Factors associated with the activity and severity of bullous pemphigoid: a review.

Authors:  Yangchun Liu; Yiman Wang; Xinyi Chen; Hongzhong Jin; Li Li
Journal:  Ann Med       Date:  2020-03-22       Impact factor: 4.709

Review 3.  Ocular mucous membrane pemphigoid: a review.

Authors:  Samanta Taurone; Marialuisa Spoletini; Massimo Ralli; Pietro Gobbi; Marco Artico; Laszlò Imre; Cecília Czakò; Illés Kovàcs; Antonio Greco; Alessandra Micera
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

Review 4.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

5.  [Bullous pemphigoid].

Authors:  F Schulze; M Kasperkiewicz; D Zillikens; E Schmidt
Journal:  Hautarzt       Date:  2013-12       Impact factor: 0.751

Review 6.  Oral manifestations of systemic disease.

Authors:  S R Porter; V Mercadante; S Fedele
Journal:  Br Dent J       Date:  2017-11-10       Impact factor: 1.626

Review 7.  Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

8.  [Anti-p200/anti-laminin γ1 pemphigoid and BP180 NC16A/4575- positive mucous membrane pemphigoid : late diagnosis in a patient with disease-related loss of vision and multiple previous surgical interventions].

Authors:  K M Kaune; M Kasperkiewicz; D Tams; M Bergmann; M Zutt
Journal:  Hautarzt       Date:  2015-01       Impact factor: 0.751

Review 9.  The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

Authors:  J K Dart
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

10.  Aldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring.

Authors:  Sarah D Ahadome; David J Abraham; Suryanarayana Rayapureddi; Valerie P Saw; Daniel R Saban; Virginia L Calder; Jill T Norman; Markella Ponticos; Julie T Daniels; John K Dart
Journal:  JCI Insight       Date:  2016-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.